RVL Pharmaceuticals (RVL Pharmaceuticals) Debt-to-Asset : 0.68 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals Debt-to-Asset?

RVL Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $57.96 Mil. RVL Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.19 Mil. RVL Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $85.40 Mil. RVL Pharmaceuticals's debt to asset for the quarter that ended in Jun. 2023 was 0.68.

RVL Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for RVL Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals Debt-to-Asset Chart

RVL Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.34

0.59

0.60

0.33

0.45

RVL Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Asset	Get a 7-Day Free Trial															0.36	0.37	0.45	0.52	0.68

Competitive Comparison of RVL Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, RVL Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RVL Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's Debt-to-Asset falls into.

RVL Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

RVL Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.877	+	55.612)	/	128.51
	=	0.45

RVL Pharmaceuticals's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(57.955	+	0.192)	/	85.404
	=	0.68

RVL Pharmaceuticals (OTCPK:RVLPQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

RVL Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

RVL Pharmaceuticals (RVL Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (OTCPK:RVLPQ) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Crossing Boulevard, Bridgewater, NJ, USA, 08807

Website

https://www.rvlpharma.com

RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

Executives

Foundation Harsaul	10 percent owner	EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA R1
Altchem Ltd	10 percent owner	KARAISKAKI 6, CITY HOUSE, LIMASSOL G4 3032
Alisa Lask	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
David F Burgstahler	director, 10 percent owner	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Athyrium Opportunities Associates Iv Co-invest Llc	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Gp Llc	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Co-invest 2 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Acquisition 2 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Funds Gp Holdings Llc	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Avista Healthcare Partners, L.p.	10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Brian A Markison	director, officer: Chief Executive Officer	501 FIFTH STREET, BRISTOL TN 37620
Sriram Venkataraman	director, 10 percent owner	C/O AVISTA CAPITAL PARTNERS, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jeffrey Ferrell	10 percent owner	ATHYRIUM CAPITAL MANAGEMENT, LP, 505 FIFTH AVENUE, FL 18, NEW YORK NY 10017
James Schaub	officer: EVP and COO	400 CROSSING BOULEVARD, C/O OSMOTICA PHARMACEUTICALS PLC, BRIDGEWATER NJ 08807